Literature DB >> 28692539

HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment.

Kasha P Singh1, Megan Crane, Jennifer Audsley, Anchalee Avihingsanon, Joe Sasadeusz, Sharon R Lewin.   

Abstract

: HIV infection has a significant impact on the natural history of chronic hepatitis B virus (HBV) infection, with increased levels of HBV DNA, accelerated progression of liver disease and increased liver-associated mortality compared with HBV monoinfection. Widespread uptake and early initiation of HBV-active antiretroviral therapy has substantially improved the natural history of HIV-HBV coinfection but the prevalence of liver disease remains elevated in this population. In this paper, we review recent studies examining the natural history and pathogenesis of liver disease and seroconversion in HIV-HBV coinfection in the era of HBV-active antiretroviral therapy and the effects of HIV directly on liver disease. We also review novel therapeutics for the management of HBV with a particular emphasis on clinical strategies being developed for an HBV cure and an HIV cure and their impact on HIV-HBV coinfected individuals.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28692539      PMCID: PMC5661989          DOI: 10.1097/QAD.0000000000001574

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  219 in total

Review 1.  Targeting hepatitis B virus cccDNA using CRISPR/Cas9.

Authors:  Edward M Kennedy; Anand V R Kornepati; Bryan R Cullen
Journal:  Antiviral Res       Date:  2015-10-22       Impact factor: 5.970

2.  Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model.

Authors:  Jun Wu; Shunmei Huang; Xiaoli Zhao; Mingfa Chen; Yong Lin; Youchen Xia; Chan Sun; Xuecheng Yang; Junzhong Wang; Yan Guo; Jingjiao Song; Ejuan Zhang; Baoju Wang; Xin Zheng; Joerg F Schlaak; Mengji Lu; Dongliang Yang
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

Review 3.  Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications.

Authors:  Teresa Pollicino; Irene Cacciola; Francesca Saffioti; Giovanni Raimondo
Journal:  J Hepatol       Date:  2014-05-05       Impact factor: 25.083

4.  Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.

Authors:  L Kosi; T Reiberger; B A Payer; K Grabmeier-Pfistershammer; R Strassl; A Rieger; M Peck-Radosavljevic
Journal:  J Viral Hepat       Date:  2012-03-15       Impact factor: 3.728

5.  The APOBEC3B deletion polymorphism is associated with prevalence of hepatitis B virus, hepatitis C virus, Torque Teno virus, and Toxoplasma gondii co-infection among HIV-infected individuals.

Authors:  Afiono Agung Prasetyo; Ratna Sariyatun; Yulia Sari; Sri Haryati; Zainal Arifin Adnan; Seiji Kageyama
Journal:  J Clin Virol       Date:  2015-07-08       Impact factor: 3.168

6.  Cohort profile: the MUg Observational Cohort.

Authors:  Anna Funk; Steve Kanters; Margaret Nansubuga; Daniel Mwehire; Amber Featherstone; Eric Druyts; Mary Odiit; Edward J Mills
Journal:  Int J Epidemiol       Date:  2012-11-19       Impact factor: 7.196

7.  Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients.

Authors:  Koffi Alain Attia; Serge Eholié; Eugène Messou; Christine Danel; Sandrine Polneau; Henri Chenal; Thomas Toni; Myreille Mbamy; Catherine Seyler; Naomi Wakasugi; Thérèse N'dri-Yoman; Xavier Anglaret
Journal:  World J Hepatol       Date:  2012-07-27

8.  TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells.

Authors:  Rujuta A Bam; Derek Hansen; Alivelu Irrinki; Andrew Mulato; Gregg S Jones; Joseph Hesselgesser; Christian R Frey; Tomas Cihlar; Stephen R Yant
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

9.  Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.

Authors:  Joel Gallant; Jason Brunetta; Gordon Crofoot; Paul Benson; Anthony Mills; Cynthia Brinson; Shinichi Oka; Andrew Cheng; Will Garner; Marshall Fordyce; Moupali Das; Scott McCallister
Journal:  J Acquir Immune Defic Syndr       Date:  2016-11-01       Impact factor: 3.731

10.  Hepatitis B virus infection in human immunodeficiency virus infected southern African adults: occult or overt--that is the question.

Authors:  Trevor G Bell; Euphodia Makondo; Neil A Martinson; Anna Kramvis
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

View more
  63 in total

Review 1.  Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV.

Authors:  Robert C Bollinger; Chloe L Thio; Mark S Sulkowski; Jane McKenzie-White; David L Thomas; Charles Flexner
Journal:  Lancet HIV       Date:  2019-12-20       Impact factor: 12.767

Review 2.  Current advances in the elimination of hepatitis B in China by 2030.

Authors:  Shuye Zhang; Fusheng Wang; Zheng Zhang
Journal:  Front Med       Date:  2017-11-23       Impact factor: 4.592

Review 3.  Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States.

Authors:  Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn
Journal:  Expert Rev Clin Pharmacol       Date:  2019-12       Impact factor: 5.045

4.  High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia.

Authors:  Belinda V Chihota; Gilles Wandeler; Roma Chilengi; Lloyd Mulenga; Raymond T Chung; Debika Bhattacharya; Mathias Egger; Michael J Vinikoor
Journal:  J Infect Dis       Date:  2020-01-02       Impact factor: 5.226

Review 5.  Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy.

Authors:  Mindie H Nguyen; Grace Wong; Edward Gane; Jia-Horng Kao; Geoffrey Dusheiko
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

6.  Brief Report: Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection.

Authors:  Timothy Archampong; Oluwayemisi Ojewale; Kristi Bears; Yiqing Chen; Margaret Lartey; Kwamena W Sagoe; Adjoa Obo-Akwa; Yan Gong; Taimour Langaee; Awewura Kwara
Journal:  J Acquir Immune Defic Syndr       Date:  2019-12-01       Impact factor: 3.731

7.  A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice.

Authors:  Weimin Wang; Nathan Smith; Edward Makarov; Yimin Sun; Catherine L Gebhart; Murali Ganesan; Natalia A Osna; Howard E Gendelman; Benson J Edagwa; Larisa Y Poluektova
Journal:  Nanomedicine       Date:  2020-03-24       Impact factor: 5.307

8.  Chronic Hepatitis B and HIV Coinfection: A Continuing Challenge in the Era of Antiretroviral Therapy.

Authors:  H Nina Kim
Journal:  Curr Hepatol Rep       Date:  2020-09-16

9.  Immune response to the hepatitis B vaccine among HIV-infected adults in Uganda.

Authors:  E Seremba; P Ocama; R Ssekitoleko; H Mayanja-Kizza; S V Adams; J Orem; E Katabira; S J Reynolds; R Nabatanzi; C Casper; W Phipps
Journal:  Vaccine       Date:  2021-01-28       Impact factor: 3.641

10.  Mortality in relation to hepatitis B virus (HBV) infection status among HIV-HBV co-infected patients in sub-Saharan Africa after immediate initiation of antiretroviral therapy.

Authors:  Amir M Mohareb; Gérard Menan Kouamé; Audrey Gabassi; Delphine Gabillard; Raoul Moh; Anani Badje; Arlette Emième; Sarah Maylin; Hervé Ménan; Emily P Hyle; Constance Delaugerre; Christine Danel; Xavier Anglaret; Karine Lacombe; Serge P Eholié; Anders Boyd
Journal:  J Viral Hepat       Date:  2021-01-23       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.